Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyMolina Healthcare Strensiq Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentMolina HealthcarePolicy C9425-A

    Perinatal/Infantile-Onset and Juvenile-Onset Hypophosphatasia

    Customize your policy alerts

    Sign up for Molina Healthcare Policy C9425-A alerts

    Get alerted when Policy C9425-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization for Strensiq (asfotase alfa) for members with documented perinatal/infantile-onset or juvenile-onset hypophosphatasia. It specifies diagnostic, laboratory, radiographic, clinical, prescriber, dosing, continuation, and documentation requirements.

    Policy Summary
    PayerMolina Healthcare
    PolicyPerinatal/Infantile-Onset and Juvenile-Onset Hypophosphatasia
    Policy CodePolicy C9425-A
    Change TypeAnnual reviewno material clinical or coverage changes
    Effective DateSep 24, 2026
    Next Review DateJul 1, 2027
    Key ActionPrior authorization is required under Molina's utilization management program.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    StrensiqProduct
    12 monthsInitial authorization
    12 monthsContinuation authorization
    2 mg/kg 3× weeklyCovered regimen

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 mg/kg/week
    Juvenile maximum dose
    9 mg/kg/weekInfantile maximum dose

    Coverage Criteria

    Initial Therapy Criteria

    Covered for initial therapy when all applicable criteria are met.

    Initial therapy

    • Qualifying TNSALP substrate abnormality: Low serum alkaline phosphatase; elevated baseline serum PLP without vitamin B6 supplementation during the previous week; elevated serum or urine PEP; or elevated urine inorganic pyrophosphate.1 of 4

      Laboratory interpretation uses the age- and gender-specific reference range of the reporting laboratory.

    • Bone findings: Provider attests to radiographic evidence of HPP confirmed by osteopenia, osteoporosis, or low bone mineral content for age detected by DEXA.
    • Adult clinical findings: For adults, clinical documentation or history of at least two skeletal and/or dental manifestations indicative of HPP.At least 2 manifestations
    • Age of onset: History of onset of HPP signs or symptoms before 18 years of age.Before 18 years of age

      Perinatal/infantile onset is before 6 months; juvenile onset is between 6 months and 18 years.

    • Baseline assessment: Prescriber documents baseline disease activity evaluation and goals for treatment to evaluate efficacy at renewal.
    • Qualified prescriber: Prescribed by, or in consultation with, a board-certified endocrinologist, geneticist, metabolic specialist, bone and mineral specialist, or physician experienced in treating metabolic bone disorders.

      Consultation notes must be submitted when prescribed in consultation.

    Continuation Therapy Criteria

    Covered for continuation therapy when all continuation criteria are met.

    Continuation therapy

    • Objective response: Objective stability and/or continued disease improvement in clinical signs or symptoms compared with baseline.

      Assess using documented baseline measures such as ventilator status, radiographic status, height and weight Z-score, gait, or mobility including the 6-minute walk test.

    • Safety and tolerability: Prescriber attests to, or clinical reviewer finds, no evidence of intolerable adverse effects or drug toxicity.

    All other uses of Strensiq (asfotase alfa) beyond treatment of perinatal/infantile-onset or juvenile-onset hypophosphatasia are considered experimental or investigational and are handled under Molina’s Off-Label policy.

    Odontohypophosphatasia limited to dental clinical symptoms is a milder form of hypophosphatasia affecting only the teeth and is not included among the covered perinatal/infantile-onset or juvenile-onset indications.

    Clinical and Coding Requirements

    TNSALP substrate abnormality
    Required laboratory evidenceAt least one qualifying TNSALP substrate abnormality is required.
    Low ALPSerum alkaline phosphatase (ALP) activity or level is low.
    Elevated PLPBaseline serum pyridoxal 5'-phosphate (PLP) is above the upper limit of normal without vitamin B6 supplementation during the previous week.
    Other qualifying elevationsSerum or urine phosphoethanolamine (PEP), or urine inorganic pyrophosphate (PPi), is elevated.
    Adult skeletal/dental manifestations
    Minimum clinical findingsAdults must have at least two skeletal and/or dental manifestations indicative of hypophosphatasia.

    Provider Submission and Authorization Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Strensiq (asfotase alfa). Coverage is subject to the member’s specific benefit plan, applicable formulary requirements, and Molina Healthcare’s medical-necessity review.

    • Submit requests for the covered diagnosis of perinatal/infantile-onset or juvenile-onset hypophosphatasia.
    • Molina evaluates coverage case by case and may require additional information, including member-specific dosing data.
    Documentation Required

    Submit Complete Medical Records and Dosing Data

    Submit a complete medical rationale and all supporting documentation with the request. Molina may request additional records, test results, and ordering-provider credentials to evaluate coverage, quality, and medical necessity.

    • Include patient records and relevant laboratory, radiographic, clinical, and dosing information.

    Disease Background

    Hypophosphatasia (HPP) is a rare inherited metabolic bone disorder caused by mutations in the ALPL gene. These mutations result in low alkaline phosphatase activity and impaired mineralization of bones and teeth. Earlier-onset disease is generally more severe and may include rickets, osteomalacia, skeletal deformities, fractures, respiratory or renal complications, vitamin B6-dependent seizures, and dental abnormalities. Strensiq (asfotase alfa) is a recombinant tissue-nonspecific alkaline phosphatase fusion protein used as enzyme replacement therapy for perinatal/infantile-onset and juvenile-onset HPP.

    Onset Definitions

    Perinatal/infantile-onset hypophosphatasia
    DefinitionPerinatal/infantile-onset hypophosphatasia is defined by onset of signs or symptoms before 6 months of age.
    Age boundaryOnset must occur before the member reaches 6 months of age.
    Covered indicationThis is one of the early-onset hypophosphatasia categories addressed by the policy.
    Juvenile-onset hypophosphatasia
    DefinitionJuvenile-onset hypophosphatasia is defined by onset of signs or symptoms between 6 months and 18 years of age.
    Lower boundaryOnset occurs at 6 months of age or later.
    Upper boundary

    Initial Strensiq Therapy

    Initial Therapy Criteria

    Initial Strensiq therapy is covered when all of the following criteria are documented.

    Initial Strensiq authorization

    • Diagnosis: Documented diagnosis of perinatal/infantile-onset or juvenile-onset hypophosphatasia.

      Perinatal/infantile onset refers to onset before 6 months; juvenile onset refers to onset between 6 months and 18 years.

    • TNSALP substrate abnormality

      • Qualifying laboratory findings: Serum alkaline phosphatase activity or level is low; baseline serum pyridoxal 5'-phosphate is elevated above the upper limit of normal without vitamin B6 supplementation during the previous week; serum or urine phosphoethanolamine is elevated; or urine inorganic pyrophosphate is elevated.1 of 4

        Interpret laboratory results using the gender- and age-specific reference range established by the reporting laboratory.

    Continuation of Strensiq

    Continuation of Strensiq

    Continuation of Strensiq is covered when all continuation criteria are met.

    • Objective response: Documentation shows that the member has responded to Strensiq, evidenced by objective stability and/or continued improvement in clinical signs or symptoms of hypophosphatasia compared with baseline.

      Relevant measures may include ventilator status, radiographic status, height and weight Z-score, gait, and mobility such as the 6-minute walk test.

    • Safety and tolerability: The prescriber attests to, or the clinical reviewer finds, no evidence of intolerable adverse effects or drug toxicity.

    Dose and Frequency Limits

    Strensiq for juvenile-onset HPP
    Applicable conditionStrensiq (asfotase alfa) for juvenile-onset hypophosphatasia.
    Maximum weekly dose6 mg/kg per week.
    Administration routeSubcutaneous administration.
    Strensiq for perinatal/infantile-onset HPP
    Applicable conditionStrensiq (asfotase alfa) for perinatal/infantile-onset hypophosphatasia.
    Maximum weekly dose9 mg/kg per week.
    Administration routeSubcutaneous administration.

    Administration Site

    Billing Rule

    Use home self-administration through the pharmacy benefit

    Injectable medication under this policy is recommended for pharmacy benefit coverage and patient self-administration at home.

    Policy Summary
    PayerMolina Healthcare
    PolicyPerinatal/Infantile-Onset and Juvenile-Onset Hypophosphatasia
    Policy CodePolicy C9425-A
    Change TypeAnnual reviewno material clinical or coverage changes
    Effective DateSep 24, 2026
    Next Review DateJul 1, 2027
    Key ActionPrior authorization is required under Molina's utilization management program.
    SourceLink
    On This Page
    Coverage CriteriaClinical and Coding RequirementsProvider Submission and Authorization RequirementsDisease BackgroundOnset DefinitionsInitial Strensiq TherapyContinuation of StrensiqDose and Frequency LimitsAdministration Site
    Skeletal manifestationsExamples include rickets, osteomalacia, rachitic deformities, craniosynostosis, delayed skeletal growth or motor development, and non-traumatic postnatal fracture with delayed healing.
    Other manifestationsExamples include vitamin B6-dependent seizures, nephrocalcinosis or elevated serum calcium, and dental manifestations such as premature loss of primary teeth or defective mineralization.
    Disease onset
    Required onsetSigns or symptoms of hypophosphatasia must have begun before 18 years of age.
    Perinatal/infantile onsetPerinatal/infantile onset means signs or symptoms began before 6 months of age.
    Juvenile onsetJuvenile onset means signs or symptoms began between 6 months and 18 years of age.
    Juvenile-onset weekly dose
    Applicable conditionJuvenile-onset hypophosphatasia.
    Maximum weekly dose6 mg/kg per week.
    RouteSubcutaneous administration.
    Perinatal/infantile-onset weekly dose
    Applicable conditionPerinatal/infantile-onset hypophosphatasia.
    Maximum weekly dose9 mg/kg per week.
    RouteSubcutaneous administration.
    Administration schedule
    Covered dose2 mg/kg per injection, three times per week.
    Covered frequencyThree-times-weekly injections only.
    Not authorizedA six-times-per-week regimen may not be authorized.
    Restricted vial use
    Restricted productStrensiq 80 mg/0.8 mL vial.
    Pediatric weight restrictionDo not use this vial in pediatric patients weighing less than 40 kg.
    Reason for restrictionThe higher-concentration vial may result in lower asfotase alfa exposure, which may be inadequate for this subgroup.
  1. Provide weight, body-surface-area, or other member-specific measurement data when dosing is based on that measurement.
  2. Documentation Required

    Document a Qualifying TNSALP Substrate Abnormality

    Document at least one qualifying TNSALP substrate abnormality using the age- and gender-specific reference range of the reporting laboratory.

    • Low serum alkaline phosphatase (ALP) activity or level; or
    • Elevated baseline serum pyridoxal 5'-phosphate (PLP), above the upper limit of normal, without vitamin B6 supplementation during the preceding week; or
    • Elevated serum or urine phosphoethanolamine (PEP); or
    • Elevated urine inorganic pyrophosphate (PPi).
    Documentation Required

    Submit Radiographic and DEXA Evidence

    Provide a provider attestation and supporting records confirming radiographic evidence of hypophosphatasia with low bone mineralization.

    • DEXA must detect osteopenia, osteoporosis, or low bone mineral content for age.
    Documentation Required

    Document Clinical Manifestations and Early Onset

    Document qualifying skeletal and/or dental manifestations and establish that HPP signs or symptoms began before age 18.

    • For adults, document at least two manifestations, such as rickets, osteomalacia, rachitic deformities, craniosynostosis, delayed skeletal growth or motor development, vitamin B6-dependent seizures, nephrocalcinosis or elevated serum calcium, non-traumatic postnatal fracture with delayed healing, or premature loss of primary teeth before age 5 or defective mineralization of bone or teeth.
    • Classify perinatal/infantile onset as before 6 months of age and juvenile onset as 6 months through before age 18.
    Documentation Required

    Establish Baseline Disease Assessment

    With the initial request, submit the prescriber’s baseline disease-activity evaluation and measurable treatment goals for assessing efficacy at renewal.

    • Examples include ventilator status, radiographic status, height and weight or Z-score, and gait or mobility measures such as the 6-minute walk test.
    Documentation Required

    Document Continuation Response and Tolerability

    For continuation requests, document objective stability or continued improvement in clinical signs or symptoms compared with baseline and confirm that treatment remains tolerable.

    • Provide comparative disease measures, such as ventilator status, radiographic status, height and weight or Z-score, and gait or mobility.
    • The prescriber must attest, or the clinical reviewer must find, no intolerable adverse effects or drug toxicity.
    Documentation Required

    Include Required Specialist Consultation Documentation

    The drug must be prescribed by, or in consultation with, a qualified specialist experienced in metabolic bone disorders. When prescribed in consultation, submit consultation notes with both the initial request and each reauthorization request.

    • Acceptable specialists include a board-certified endocrinologist, geneticist, metabolic specialist, bone and mineral specialist, or physician specialist experienced in treating metabolic bone disorders.
    Denial Risk

    Adult-Onset Disease Is Not Covered

    Adult-onset HPP does not meet this policy’s coverage criteria. The onset of signs or symptoms must occur before the member reaches 18 years of age.

    • Onset at age 18 years or older is excluded, even when the member has a qualifying HPP diagnosis.
    Denial Risk

    Noncovered Regimen or Indication

    Do not request or bill a six-times-weekly regimen under this policy, and do not use Strensiq for indications outside the covered HPP criteria. Such requests are not covered under this policy and may be treated as experimental/investigational under Molina’s Off-Label policy.

    • Covered regimen: 2 mg/kg subcutaneously three times weekly.
    • Maximum weekly quantity: 6 mg/kg/week for juvenile-onset HPP and 9 mg/kg/week for perinatal/infantile-onset HPP.
    • Other uses, including odontohypophosphatasia presenting only with dental symptoms, are not covered by this policy.
    Billing Rule

    Restricted Pediatric Vial

    Do not use the 80 mg/0.8 mL Strensiq vial in pediatric patients weighing less than 40 kg. The higher-concentration vial may result in inadequate systemic exposure for this subgroup.

    • Select an appropriate vial strength for pediatric patients under 40 kg.
    • This restriction applies regardless of whether the requested treatment otherwise meets coverage criteria.
    Denial Risk

    Insufficient Supporting Documentation May Result in Denial

    Insufficient or unsupported documentation may result in denial of reimbursement or other appropriate action. Molina may determine that the drug is not medically necessary, investigational or experimental, outside the member’s benefits, or associated with inappropriate or excessive billing practices.

    • Maintain complete records supporting the initial determination and submit additional documentation when requested.
    • Documentation requirements may support coverage determination, quality improvement, and fraud, waste, and abuse prevention.
    Onset occurs before 18 years of age.
    Adult-onset hypophosphatasia
    DefinitionAdult-onset hypophosphatasia is defined by onset of signs or symptoms at 18 years of age or older.
    Age thresholdOnset at age 18 or older is classified as adult-onset disease.
    Policy statusAdult-onset hypophosphatasia does not meet the policy criteria.
  3. Radiographic and bone findings: Provider attests to radiographic evidence of HPP confirmed by osteopenia, osteoporosis, or low bone mineral content for age detected by DEXA.
  4. Adult clinical findings: For adults, clinical documentation or documented history of at least two skeletal and/or dental manifestations indicative of HPP.At least 2 manifestations

    Examples include rickets, osteomalacia, rachitic deformities, craniosynostosis, delayed skeletal growth or motor development, vitamin B6-dependent seizures, nephrocalcinosis or elevated serum calcium, non-traumatic postnatal fracture with delayed healing, and dental manifestations.

  5. Age of onset: History documents that HPP signs or symptoms began before 18 years of age.Before 18 years of age

    Adult-onset HPP, defined as onset at 18 years or older, does not meet the criteria.

  6. Baseline disease assessment: Prescriber documents baseline disease activity evaluation and treatment goals for evaluating efficacy at renewal.

    Examples include ventilator status, radiographic status, height and weight Z-score, gait, and mobility such as the 6-minute walk test.

  7. Qualified prescriber: Strensiq is prescribed by, or in consultation with, a board-certified endocrinologist, geneticist, metabolic specialist, bone and mineral specialist, or physician experienced in treating metabolic bone disorders.

    If prescribed in consultation, consultation notes must be submitted with the initial request and reauthorization requests.

  8. Strensiq administration
    Covered dose2 mg/kg per injection, three times per week.
    Covered regimenStrensiq is covered as a three-times-per-week injection.
    Not authorizedA six-times-per-week regimen may not be authorized.